Literature DB >> 32498602

Topography of Cholinergic Changes in Dementia With Lewy Bodies and Key Neural Network Hubs.

Prabesh Kanel1, Martijn L T M Müller1, Sygrid van der Zee1, Carlos A Sanchez-Catasus1, Robert A Koeppe1, Kirk A Frey1, Nicolaas I Bohnen1.   

Abstract

OBJECTIVES: The authors investigated the topography of cholinergic vulnerability in patients with dementia with Lewy bodies (DLB) using positron emission tomography (PET) imaging with the vesicular acetylcholine transporter (VAChT) [18F]-fluoroethoxybenzovesamicol ([18F]-FEOBV) radioligand.
METHODS: Five elderly participants with DLB (mean age, 77.8 years [SD=4.2]) and 21 elderly healthy control subjects (mean age, 73.62 years [SD=8.37]) underwent clinical assessment and [18F]-FEOBV PET.
RESULTS: Compared with the healthy control group, reduced VAChT binding in patients with DLB demonstrated nondiffuse regionally distinct and prominent reductions in bilateral opercula and anterior cingulate to mid-cingulate cortices, bilateral insula, right (more than left) lateral geniculate nuclei, pulvinar, right proximal optic radiation, bilateral anterior and superior thalami, and posterior hippocampal fimbria and fornices.
CONCLUSIONS: The topography of cholinergic vulnerability in DLB comprises key neural hubs involved in tonic alertness (cingulo-opercular), saliency (insula), visual attention (visual thalamus), and spatial navigation (fimbria/fornix) networks. The distinct denervation pattern suggests an important cholinergic role in specific clinical disease-defining features, such as cognitive fluctuations, visuoperceptual abnormalities causing visual hallucinations, visuospatial changes, and loss of balance caused by DLB.

Entities:  

Keywords:  Cognition; Dementia; Dementia With Lewy Bodies; Neurology; Saliency

Mesh:

Substances:

Year:  2020        PMID: 32498602     DOI: 10.1176/appi.neuropsych.19070165

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  9 in total

Review 1.  Molecular Imaging of the Cholinergic System in Alzheimer and Lewy Body Dementias: Expanding Views.

Authors:  Prabesh Kanel; Marc-André Bedard; Meghmik Aghourian; Pedro Rosa-Neto; Jean-Paul Soucy; Roger L Albin; Nicolaas I Bohnen
Journal:  Curr Neurol Neurosci Rep       Date:  2021-09-20       Impact factor: 6.030

2.  Differential cholinergic systems' changes in progressive supranuclear palsy versus Parkinson's disease: an exploratory analysis.

Authors:  Prabesh Kanel; C Chauncey Spears; Stiven Roytman; Robert A Koeppe; Kirk A Frey; Peter J H Scott; Roger L Albin; Nicolaas I Bohnen
Journal:  J Neural Transm (Vienna)       Date:  2022-10-12       Impact factor: 3.850

Review 3.  Basal Forebrain Impairment: Understanding the Mnemonic Function of the Septal Region Translates in Therapeutic Advances.

Authors:  Marian Tsanov
Journal:  Front Neural Circuits       Date:  2022-05-31       Impact factor: 3.342

4.  Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease.

Authors:  Sygrid van der Zee; Martijn L T M Müller; Prabesh Kanel; Teus van Laar; Nicolaas I Bohnen
Journal:  Mov Disord       Date:  2020-11-02       Impact factor: 10.338

5.  Influence of Acetylcholine Esterase Inhibitors and Memantine, Clinically Approved for Alzheimer's Dementia Treatment, on Intestinal Properties of the Mouse.

Authors:  Vu Thu Thuy Nguyen; Jason Sallbach; Malena Dos Santos Guilherme; Kristina Endres
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 5.923

6.  Cerebral topography of vesicular cholinergic transporter changes in neurologically intact adults: A [18F]FEOBV PET study.

Authors:  Prabesh Kanel; Sygrid van der Zee; Carlos A Sanchez-Catasus; Robert A Koeppe; Peter J H Scott; Teus van Laar; Roger L Albin; Nicolaas I Bohnen
Journal:  Aging Brain       Date:  2022-03-28

7.  Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment.

Authors:  Sygrid van der Zee; Prabesh Kanel; Marleen J J Gerritsen; Jeffrey M Boertien; Anne C Slomp; Martijn L T M Müller; Nicolaas I Bohnen; Jacoba M Spikman; Teus van Laar
Journal:  Mov Disord       Date:  2022-01-17       Impact factor: 9.698

8.  Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration.

Authors:  Ying Jiang; John J Alam; Stephen N Gomperts; Paul Maruff; Afina W Lemstra; Ursula A Germann; Philip H Stavrides; Sandipkumar Darji; Sandeep Malampati; James Peddy; Cynthia Bleiwas; Monika Pawlik; Anna Pensalfini; Dun-Sheng Yang; Shivakumar Subbanna; Balapal S Basavarajappa; John F Smiley; Amanda Gardner; Kelly Blackburn; Hui-May Chu; Niels D Prins; Charlotte E Teunissen; John E Harrison; Philip Scheltens; Ralph A Nixon
Journal:  Nat Commun       Date:  2022-09-21       Impact factor: 17.694

Review 9.  Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance.

Authors:  Changiz Geula; Sara R Dunlop; Ivan Ayala; Allegra S Kawles; Margaret E Flanagan; Tamar Gefen; Marek-Marsel Mesulam
Journal:  J Neurochem       Date:  2021-08-06       Impact factor: 5.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.